case_images: PMC5577842_01
case_images: Changes in serum free and total IgE levels over time before and after omalizumab administration. Changes in serum free IgE (Black up-pointing triangle) and total IgE (Black square) levels are shown before commencing omalizumab (-1 week) to 172 weeks after beginning administration. The longitudinal axis represents the logarithmic expression of serum IgE levels
case_images: 13223_2017_211_Fig1_HTML.jpg
case_images: PMC5577842_01_13223_2017_211_Fig1_HTML.jpg
case_images: Fig1
case_images: We measured her serum free IgE levels at 2, 4, 8, and 26 weeks after initiating omalizumab and found that the serum free IgE levels were extremely low at 72.8, 40.50, 18.1, and 11.3 ng/dL, respectively (Fig. 1). The serum free IgE trough level transiently increased to 129.3 ng/mL at 4 weeks after reducing the dosage; however, thereafter, the serum free IgE level decreased to 93.6 ng/mL within 4 weeks and gradually to 20.6 ng/mL, which is well below the desired level, 30 ng/mL (Fig. 1). FEV1 measured via pulmonary function testing almost unchanged after reduction of omalizumab (Fig. 1).